Skip to main content Accessibility help
×
Home

Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia

  • Y.-T. Xiang (a1), G. S. Ungvari (a2), C. U. Correll (a3), H. F. K. Chiu (a4) and N. Shinfuku (a5)...

Abstract

To date, antipsychotics remain the mainstay of treatment for schizophrenia and related disorders although other psychotropic medications and non-pharmaceutical interventions have been used adjunctively in some patients and settings. Regular surveys on access to and prescription patterns of psychotropic medications in clinical practice are an important and efficient way of examining the use and time trends of treatments in a given population and region. Unlike developed Western countries, Asian countries have not fully undergone deinstitutionalisation of the severely and chronically mentally ill, and community-based mental health services are still under-developed. As a result, a large number of psychiatric patients still receive treatments in psychiatric hospitals. Moreover, there have been very limited studies examining access to and prescription patterns of psychotropic medications for schizophrenia patients in Asian countries. In this paper, we focus on the only international project on the use of psychotropic medications in schizophrenia patients in selected East and Southeast Asian countries/territories summarising its major findings. Most of the first- and second-generation antipsychotics (FGAs and SGAs) are available in Asian countries, but the access to psychotropic medications is largely affected by socio-cultural and historical contexts, health insurance schemes, health care policy, medication cost and consumers’ preference across different countries/territories. Overall, the proportional use of FGAs, high dose antipsychotic treatment and antipsychotic polypharmacy have decreased, while the use of SGAs and antidepressants have increased and the utilisation of benzodiazepines and mood stabilisers has remained relatively stable over time. However, within these general trends, there is great inter-country variation regarding the psychotropic prescribing patterns and trends in Asian schizophrenia patients that also seems to differ from data in many Western countries.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
      Available formats
      ×

Copyright

Corresponding author

*Address correspondence: Dr Y.-T. Xiang, Faculty of Health Sciences, University of Macau, Avenida da Universidade, 3/F, Building E12, Taipa, Macau SAR, China. (E-mail: xyutly@gmail.com)

References

Hide All
Barbui, C, Signoretti, A, Mule, S, Boso, M, Cipriani, A (2009). Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophrenia Bulletin 35, 458468.
Binder, RL, Kazamatsuri, H, Nishimura, T, McNiel, DE (1987). Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. American Journal of Psychiatry 144, 14941496.
Bowers, L, Callaghan, P, Clark, N, Evers, C (2004). Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. European Journal of Clinical Pharmacology 60, 2935.
Buchanan, RW, Kreyenbuhl, J, Kelly, DL, Noel, JM, Boggs, DL, Fischer, BA, Himelhoch, S, Fang, B, Peterson, E, Aquino, PR, Keller, W (2010). The 2009 schizophrenia PORT psycho-pharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 7193.
Byerly, M, Suppes, T, Tran, QV, Baker, RA (2007). Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. Journal of Clinical Psychopharmacology 27, 639661.
Castle, D, Morgan, V, Jablensky, A (2002). Antipsychotic use in Australia: the patients’ perspective. Australian and New Zealand Journal of Psychiatry 36, 633641.
Chakos, MH, Glick, ID, Miller, AL, Hamner, MB, Miller, DD, Patel, JK, Tapp, A, Keefe, RS, Rosenheck, RA (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services 57, 10941101.
Chen, H, Kennedy, WK, Dorfman, JH, Fincham, JE, Reeves, J, Martin, BC (2007). The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Current Medical Research and Opinion 23, 13511365.
Chong, MY, Tan, CH, Fujii, S, Yang, SY, Ungvari, GS, Si, T, Chung, EK, Sim, K, Tsang, HY, Shinfuku, N (2004). Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry and Clinical Neurosciences 58, 6167.
Citrome, L (1995). Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. Journal of Pharmacy Technology 11, 5559.
Citrome, L, Levine, J, Allingham, B (2000). Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51, 634638.
Conley, RR (2009). The burden of depressive symptoms in people with schizophrenia. Psychiatric Clinics of North America 32, 853861.
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443457.
Correll, CU, Kishimoto, T, Kane, JM (2011). Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in Clinical NeuroSciences 13, 155172.
Elie, D, Poirier, M, Chianetta, J, Durand, M, Gregoire, C, Grignon, S (2010). Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology 24, 10371044.
Essock, SM, Schooler, NR, Stroup, TS, McEvoy, JP, Rojas, I, Jackson, C, Covell, NH (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 168, 702708.
Fujii, S, Shinfuku, N (2005). Utilization of levomepromazine in Japan – Its role as an antipsychotic in psychiatric pharmacotherapy (In Japanese). Rinsyo Seisin Yakuri 8, 12271238.
Gallego, JA, Bonetti, J, Zhang, J, Kane, JM, Correll, CU (2012 a). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research 138, 1828.
Gallego, JA, Nielsen, J, De Hert, M, Kane, JM, Correll, CU (2012 b). Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety 11, 527542.
Haro, JM, Salvador-Carulla, L (2006). The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 20, 293301.
Hecht, EM, Landy, DC (2012). Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophrenia Research 134, 202206.
Himelhoch, S, Slade, E, Kreyenbuhl, J, Medoff, D, Brown, C, Dixon, L (2012). Antidepressant prescribing patterns among VA patients with schizophrenia. Schizophrenia Research, doi:10.1016/j.schres.2012.1001.1008.
Huskamp, HA (2005). Pharmaceutical cost management and access to psychotropic drugs: the US context. International Journal of Law and Psychiatry 28, 484495.
Idanpaan-Heikkila, J, Alhava, E, Olkinuora, M, Palva, I (1975). Letter: clozapine and agranulocytosis. Lancet 2, 611.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789796.
Kreyenbuhl, J, Buchanan, RW, Dickerson, FB, Dixon, LB (2010). The schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 36, 94103.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, RR, Geddes, JR, Kissling, W, Stapf, MP, Lassig, B, Salanti, G, Davis, JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951962.
Li, LH, Zhao, JP, Xu, XF, Meng, QH, Ning, J (2006). A comparative study of locally manufactured intramuscular ziprasidone and haloperidol in treating acute atitation in schizophrenia (in Chinese). Chinese Journal of Psychiatry 39, 216219.
Liu, TL, Li, CY (2003). The comparison of use of antipsychotics in first-episode patients with schizophrenia (in Chinese). Medical journal of Chinese people Health 15, 289290.
Martin, K, Begaud, B, Latry, P, Miremont-Salame, G, Fourrier, A, Moore, N (2004). Differences between clinical trials and post-marketing use. British Journal of Clinical Pharmacology 57, 8692.
Parepally, H, Chakravorty, S, Levine, J, Brar, JS, Patel, AM, Baird, JW, Chalasani, L, Delaney, JA, Atzert, R, Chengappa, KN (2002). The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 437440.
Pickar, D, Vinik, J, Bartko, JJ (2008). Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE 3, e3150.
Pierre, JM (2005). Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety 28, 191208.
Rothbard, AB, Kuno, E, Foley, K (2003). Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29, 531540.
Rummel, C, Kissling, W, Leucht, S (2006). Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews 3, CD005581.
Sepehry, AA, Potvin, S, Elie, R, Stip, E (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 604610.
Shinfuku, N, Tan, CH (2008). Pharmacotherapy for schizophrenic inpatients in East Asia--changes and challenges. International Review of Psychiatry 20, 460468.
Si, TM (2014). The Third Survey of Prescription Pattern of Psychotropic Drugs in China: Schizophrenia Patients Prescription Status. In The Chinese Society of Neuroscience & Psychiatry Annual Meeting, Nanchang.
Singh, SP, Singh, V, Kar, N, Chan, K (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry 197, 174179.
Tani, H, Uchida, H, Suzuki, T, Fujii, Y, Mimura, M (2013). Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophrenia Research 143, 215220.
Tiihonen, J, Suokas, JT, Suvisaari, JM, Haukka, J, Korhonen, P (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry 69, 476483.
Tor, PC, Ng, TP, Yong, KH, Sim, K, Xiang, YT, Wang, CY, Lee, EH, Fujii, S, Yang, SY, Chong, MY, Ungvari, GS, Si, T, He, YL, Chung, EK, Chee, KY, Trivedi, J, Udomratn, P, Shinfuku, N, Kua, EH, Tan, CH, Sartorius, N, Baldessarini, RJ (2011). Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. International Journal of Neuropsychopharmacology 14, 735745.
Ungvari, GS, Chow, LY, Chiu, HF, Ng, FS, Leung, T (1997). Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry and Clinical Neurosciences 51, 309314.
Webb, WB, Agnew, HW (1975). Are we chronically sleep deprived? Bulletin of the Psychonomic Society 6, 4748.
WHO Collaborating Centre for Drug Statistic Methodology (2002). Guidelines for ATC Index with DDDs. WHO: Oslo.
World Health Organization (2011). Mental Health Atlas – 2011 Country Profiles. WHO: Geneva, Switzerland.
Xiang, YT, Weng, YZ, Leung, CM, Tang, WK, Ungvari, GS (2007 a). Clinical and social determinants of long-term use of benzodiazepines and its impact on quality of life of Chinese schizophrenia patients. Pharmacopsychiatry 40, 269274.
Xiang, YT, Weng, YZ, Leung, CM, Tang, WK, Ungvari, GS (2007 b). Clinical correlates of clozapine prescription for schizophrenia in China. Human Psychopharmacology 22, 1725.
Xiang, YT, Dickerson, F, Kreyenbuhl, J, Ungvari, GS, Wang, CY, Si, TM, Lee, EH, He, YL, Chiu, HF, Yang, SY, Chong, MY, Tan, CH, Kua, EH, Fujii, S, Sim, K, Yong, MK, Trivedi, JK, Chung, EK, Udomratn, P, Chee, KY, Sartorius, N, Shinfuku, N (2012 a). Adjunctive mood stabilizer and benzodiazepine use in older Asian patients with schizophrenia, 2001–2009. Pharmacopsychiatry 45, 217222.
Xiang, YT, Kreyenbuhl, J, Dickerson, FB, Ungvari, GS, Wang, CY, Si, TM, Lee, EH, He, YL, Chiu, HF, Yang, SY, Chong, MY, Tan, CH, Kua, EH, Fujii, S, Sim, K, Yong, MK, Trivedi, JK, Chung, EK, Udomratn, P, Chee, KY, Sartorius, N, Shinfuku, N (2012 b). Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001–2009). Australian and New Zealand Journal of Psychiatry 46, 11591164.
Xiang, YT, Wang, CY, Si, TM, Lee, EH, He, YL, Ungvari, GS, Chiu, HF, Yang, SY, Chong, MY, Tan, CH, Kua, EH, Fujii, S, Sim, K, Yong, KH, Trivedi, JK, Chung, EK, Udomratn, P, Chee, KY, Sartorius, N, Shinfuku, N (2012 c). Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry 45, 712.
Xiang, YT, Ungvari, GS, Wang, CY, Si, TM, Lee, EH, Chiu, HF, Lai, KY, He, YL, Yang, SY, Chong, MY, Tan, CH, Kua, EH, Fujii, S, Sim, K, Yong, MK, Trivedi, JK, Chung, EK, Udomratn, P, Chee, KY, Sartorius, N, Shinfuku, N (2013). Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001–2009). Asia-Pacific Psychiatry 5, E81E87.
Yin, HR, Huang, RH, Chen, X, Zhang, LR (2005). The effect of locally manufactured aripiprazole in treatment of first episode schizophrenia (in Chinese). Journal of Clinical Research 22, 10001001.
Zhang, JP, Gallego, JA, Robinson, DG, Malhotra, AK, Kane, JM, Correll, CU (2013). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology 16, 12051218.

Keywords

Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia

  • Y.-T. Xiang (a1), G. S. Ungvari (a2), C. U. Correll (a3), H. F. K. Chiu (a4) and N. Shinfuku (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed